<DOC>
	<DOCNO>NCT00903552</DOCNO>
	<brief_summary>This phase 2A randomize , double blind , placebo control trial evaluate safety immunogenicity trivalent seasonal influenza virus-like particle ( VLP ) vaccine ( recombinant ) healthy adult .</brief_summary>
	<brief_title>Trial Evaluate Safety Immunogenicity Trivalent Seasonal Influenza Virus-Like Particle ( VLP ) Vaccine ( Recombinant )</brief_title>
	<detailed_description>The primary study objective : - To assess tolerability safety Influenza VLP Vaccine - To assess immunogenicity Influenza VLP Vaccine measure hemagglutination inhibition ( HAI ) antibody titer component viral strain</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female 18 49 year age time vaccination 2 . Informed consent must obtain subject prior beginning study specific procedure indicate understand purpose study willing adhere procedure describe protocol 3 . Available telephone ( Novavax , Inc . CONFIDENTIAL 22 Apr2009 ; NVX 755.203 Version 2.0 Page 22 52 ) 4 . Free obvious health problem chronic illness ( i.e. , recent exacerbation acute episode chronic illness last 6 month ) establish medical history , review system , clinical examination enter study : This include mental condition would interfere subject selfassessment Subjects preexist chronic disease ( limited hypertension , diabetes , hypothyroidism ) allow participate disease stable ( stable disease define new onset exacerbation preexist chronic disease 6 month prior study vaccine injection ) 5 . If subject childbearing potential , must abstinent use adequate contraceptive precaution ( e.g. , intrauterine contraceptive device ; oral contraceptive equivalent hormonal contraception ) 2 month prior vaccination . She must also negative pregnancy test study entry must agree continue precaution three month vaccination 1 . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede administration study vaccine , plan use study period 2 . Has receive license investigational influenza vaccine within 12 month prior enrollment study expect receipt influenza vaccination final immune response blood collection 3 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior administration study vaccine The use inhale nasal steroid permit 4 . Any medically diagnose suspect immunodeficient condition base medical history physical examination 5 . Administration immunoglobulins and/or blood product within three month precede administration study vaccine study 6 . Acute disease time enrollment . Acute disease define presence moderate severe illness without fever &gt; 100.5Â°F 7 . Acute clinically significant pulmonary ( e.g. , asthma ) , cardiovascular , hepatic renal functional abnormality determine physical examination laboratory screen test 8 . Major congenital defect 9 . History neurological disorder seizure , exception febrile seizures childhood 10 . Pregnant lactate female 11 . Females plan become pregnant planning discontinue contraceptive precaution within 60 day enrollment study 12 . Any condition opinion investigator would interfere evaluation vaccine interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>